ストックスクリーナーアプリを入手
3.475
4.51%
-0.1643
アフターアワーズ：
3.36
-0.115
-3.31%
前日終値:
$3.6393
開ける：
$3.64
24時間の取引高:
28,971
Relative Volume:
0.35
時価総額：
$2.60M
収益：
$4.79M
当期純損益:
$-13.42M
株価収益率:
-1.3064
EPS:
-2.66
ネットキャッシュフロー:
$-10.30M
1週間 パフォーマンス:
+7.25%
1か月 パフォーマンス:
+3.53%
6か月 パフォーマンス:
-42.80%
1年 パフォーマンス:
-76.60%
1日の値動き範囲:
$3.252
$3.645
1週間の範囲:
$3.20
$4.3999
52週間の値動き範囲:
$2.85
$29.43
Qualigen Therapeutics Inc Stock (QLGN) Company Profile
名前
Qualigen Therapeutics Inc
セクター
電話
(760) 918-9165
住所
2042 CORTE DEL NOGAL, CALIFORNIA
QLGN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
QLGN
Qualigen Therapeutics Inc
|
3.475 | 2.60M | 4.79M | -13.42M | -10.30M | -2.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Qualigen Therapeutics Inc (QLGN) 最新ニュース
QLGN stock touches 52-week low at $2.9 amid market challenges By Investing.com - Investing.com South Africa
QLGN stock touches 52-week low at $2.9 amid market challenges - Investing.com India
Qualigen Therapeutics (NASDAQ:QLGN) Shares Down 1.2% – Should You Sell? - Defense World
Qualigen Therapeutics Delays Yearly Financial Report - TipRanks
Qualigen seeks to enter the $10 Billion CABG market with non-binding MOU to acquire Marizyme - GlobeNewswire
Qualigen Therapeutics to acquire Marizyme in strategic move - Investing.com
Qualigen Therapeutics to acquire Marizyme in strategic move By Investing.com - Investing.com South Africa
Qualigen Therapeutics, Inc. (NASDAQ:QLGN) Short Interest Up 49.4% in January - Defense World
Qualigen to invest in NanoSynex, stock tumbles 21% - MSN
Qualigen Therapeutics Invests in NanoSynex’s Growth - TipRanks
Qualigen to participate in next funding round for NanoSynex - GlobeNewswire
This Breakthrough Could Cut Antibiotic Testing Time in HalfQualigen's Strategic Investment - StockTitan
Microbiomes Market to Grow by USD 1.13 Billion (2024-2028), Driven by Rising Disease Prevalence; AI Impact on Market TrendsTechnavio - The Malaysian Reserve
Qualigen Therapeutics (NASDAQ:QLGN) Stock Price Down 5.2% – Time to Sell? - Defense World
Qualigen Therapeutics (NASDAQ:QLGN) Shares Down 5.2% – Here’s Why - Defense World
Qualigen Therapeutics (NASDAQ:QLGN) Trading Down 7.8% – Time to Sell? - Defense World
SEC Form S-1 filed by Qualigen Therapeutics Inc. - Quantisnow
Qualigen Therapeutics regains compliance with Nasdaq's listing requirements - MSN
Qualigen Therapeutics regains Nasdaq compliance By Investing.com - Investing.com UK
Qualigen Therapeutics Announces Regained Compliance with - GlobeNewswire
Qualigen Therapeutics Announces Regained Compliance with Nasdaq's Minimum Bid Price Requirement and the Equity Requirement - Yahoo Finance
Univest Securities, LLC Announces Successful Closing of $5.1 Million Private Placement for Qualigen Therapeutics, Inc. (NASDAQ: QLGN) - The Manila Times
Univest Securities, LLC Announces Successful Closing of - GlobeNewswire
Qualigen Therapeutics, Inc. announced that it expects to receive $5.1 million in funding - Marketscreener.com
Qualigen Therapeutics secures $4.5 million in funding By Investing.com - Investing.com South Africa
Qualigen Therapeutics secures $4.5 million in funding - Investing.com India
Qualigen Therapeutics Announces $4.5 Million Private Placement of Convertible Preferred Shares - The Manila Times
Qualigen Therapeutics (NASDAQ:QLGN) versus Ionis Pharmaceuticals (NASDAQ:IONS) Head-To-Head Review - Defense World
Qualigen Therapeutics Inc (QLGN) Quarterly 10-Q Report - Quartzy
Qualigen Therapeutics appoints new board member - Investing.com
Qualigen Therapeutics appoints new board member By Investing.com - Investing.com Canada
Qualigen Therapeutics Appoints Graydon Bensler to Board - TipRanks
QLGN Stock Touches 52-Week Low at $3.71 Amid Market Challenges - Investing.com Canada
Qualigen Therapeutics announces 1-for-50 reverse stock split - Investing.com India
Qualigen Therapeutics announces 1-for-50 reverse stock split By Investing.com - Investing.com UK
Qualigen Therapeutics (STU:7R90) Enterprise Value : €4.58 Mil (As of Nov. 07, 2024) - GuruFocus.com
Qualigen Therapeutics (STU:7R90) Operating Cash Flow per Sh - GuruFocus.com
Qualigen Therapeutics (STU:7R90) Financial Strength : 4 (As of Jun. 2024) - GuruFocus.com
Qualigen Therapeutics (STU:7R90) Shares Outstanding (EOP) : 0.19 Mil (As of Jun. 2024) - GuruFocus.com
Qualigen Therapeutics (STU:7R90) Long-Term Debt & Capital L - GuruFocus.com
Qualigen Therapeutics (STU:7R90) EV-to-Revenue : (As of Nov. 07, 2024) - GuruFocus.com
Qualigen Therapeutics (STU:7R90) Cash Flow from Financing : €1.51 Mil (TTM As of Jun. 2024) - GuruFocus.com
Qualigen Therapeutics, Inc. Announces Chief Financial Officer Changes - Marketscreener.com
Qualigen Therapeutics, Inc. Announces Appointment of Amy Broidrick as Executive Vice President and Chief Strategy Officer - Marketscreener.com
QLGN stock touches 52-week high at $5.05 amid market fluctuations - Investing.com
Qualigen Therapeutics Stock to Reverse Split on Tuesday, November 5th (NASDAQ:QLGN) - Defense World
Shares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024 - GlobeNewswire
Would I Buy Qualigen Therapeutics Inc (NASDAQ: QLGN) Stock At Any Time In The Future? - Stocks Register
Qualigen Therapeutics announces results of annual stockholder meeting By Investing.com - Investing.com Australia
Qualigen Therapeutics Inc (QLGN) 財務データ
収益
当期純利益
現金流量
EPS
0.24%
36.06%
大文字化:
|
ボリューム (24 時間):